The sequence of therapies like bispecifics and CAR-T critically impacts future options and outcomes. This necessitates early, strategic collaboration between community oncologists and academic centers to plan a patient's entire treatment journey, not just the next immediate step.

Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

The durability of CAR-T responses is prompting a paradigm shift. With a plateau forming on survival curves, where a third of heavily pretreated patients remain relapse-free five years post-infusion, experts are now seriously discussing how to formally define a 'cure' for multiple myeloma.

Data from the MAJESTIC three trial shows bispecific antibodies achieving progression-free survival rates comparable to CAR-T therapy. This creates a new clinical dilemma, forcing a choice between an immediate, off-the-shelf option for rapid progression versus a one-time therapy with a longer track record, making treatment an individualized decision.

With highly effective treatments like CAR-T and bispecifics moving into earlier lines of therapy for multiple myeloma, the clinical focus must evolve. While efficacy benchmarks have been met, the next advancement requires vigilant attention to safety, particularly infection risks and other side effects of new paradigms.

A convergence of data from pivotal trials (MAJESTIC, CARTITUDE) establishes that BCMA-directed therapies, including CAR-T and bispecifics, provide superior outcomes in early relapse. This marks a paradigm shift, making them the new standard of care after initial therapy failure, even in patients refractory to prior common treatments.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

Five-year follow-up from the CARTITUDE-1 trial suggests a potential cure for multiple myeloma is achievable. With roughly one-third of heavily pretreated patients remaining in remission at five years—and some confirmed as MRD-negative—the concept of a cure is now part of the operational discussion among specialists, a monumental shift for a disease long considered incurable.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.